- Home
- AMRN vs GNFT Comparison
AMRN vs GNFT Comparison
Compare AMRN & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMRN
- GNFT
- Stock Information
- Founded
- AMRN 1989
- GNFT 1999
- Country
- AMRN Ireland
- GNFT France
- Employees
- AMRN N/A
- GNFT N/A
- Industry
- AMRN Biotechnology: Pharmaceutical Preparations
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AMRN Health Care
- GNFT Health Care
- Exchange
- AMRN Nasdaq
- GNFT Nasdaq
- Market Cap
- AMRN 216.0M
- GNFT 186.3M
- IPO Year
- AMRN 1993
- GNFT 2019
- Fundamental
- Price
- AMRN $16.08
- GNFT $3.83
- Analyst Decision
- AMRN Strong Sell
- GNFT Strong Buy
- Analyst Count
- AMRN 1
- GNFT 1
- Target Price
- AMRN $12.00
- GNFT $13.00
- AVG Volume (30 Days)
- AMRN 174.2K
- GNFT 4.0K
- Earning Date
- AMRN 07-30-2025
- GNFT 04-24-2025
- Dividend Yield
- AMRN N/A
- GNFT N/A
- EPS Growth
- AMRN N/A
- GNFT N/A
- EPS
- AMRN N/A
- GNFT 0.03
- Revenue
- AMRN $214,112,000.00
- GNFT $73,187,701.00
- Revenue This Year
- AMRN N/A
- GNFT $15.98
- Revenue Next Year
- AMRN N/A
- GNFT N/A
- P/E Ratio
- AMRN N/A
- GNFT $120.71
- Revenue Growth
- AMRN N/A
- GNFT 105.01
- 52 Week Low
- AMRN $7.08
- GNFT $2.55
- 52 Week High
- AMRN $17.49
- GNFT $6.42
- Technical
- Relative Strength Index (RSI)
- AMRN 71.53
- GNFT 41.57
- Support Level
- AMRN $16.12
- GNFT $3.44
- Resistance Level
- AMRN $17.49
- GNFT $3.81
- Average True Range (ATR)
- AMRN 0.96
- GNFT 0.17
- MACD
- AMRN 0.05
- GNFT -0.01
- Stochastic Oscillator
- AMRN 90.37
- GNFT 38.18
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.